Sanofi (France) Relying On Partnership With Regeneron Pharmaceuticals, Inc. To Save Its R&D Reputation
French drugmaker Sanofi has been one of the weaker players in the industry in terms of new product launches in recent years, but that is set to change, says chief executive Chris Viehbacher. Discussing the company's R&D heritage on Sanofi's fourth-quarter results call, Viehbacher conceded that Sanofi "hasn't brought a lot of new products to market in the last 10 years", with drugs launched since 2009 contributing less than €1bn to its turnover last year. Now, Sanofi has it has "one of the better pipelines in the industry" said Viehbacher, with nine late-stage projects that may potentially be filed over the next 4 years in several disease areas, including diabetes, vaccines, cardiovascular and immunology.
Help employers find you! Check out all the jobs and post your resume.